Magna Scientia Advanced Research and Reviews

eISSN: 2582-9394

Cross Ref DOI: 10.30574/msarr

Journal homepage: https://magnascientiapub.com/journals/msarr/

(REVIEW ARTICLE)

Check for updates

Cascading defenses: A multifaceted narrative of immune responses in head and neck physiology

Mira Al Shoufy [1], Naseeb Danaf [1], Kholoud Al Jebawi [1, 2], Sandra Said Aboudaher [1], Adel Ayash [1], Ahmad Al Kadi [1], Batoul Shokor [1], Fatima Zeidan [1], Nourhan Kanso [1], Razan Salha [1], Shubh Prashant Mehta [3], Mohammad Shamseddine [1] and Jamil Nasrallah [1, 2, *]

[1] *Department of Medicine, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.*
[2] *Department of Life Sciences, Faculty of Sciences, Lebanese University, Beirut, Lebanon.*
[3] *Department of Internal Medicine, Civil Hospital and BJ Medical College, Ahmedabad, India.*

Magna Scientia Advanced Research and Reviews, 2024, 10(01), 194–222

Publication history: Received on 22 December 2023; revised on 03 February 2024; accepted on 06 February 2024

Article DOI: https://doi.org/10.30574/msarr.2024.10.1.0018

Abstract

This scholarly investigation provides an exhaustive exploration of the intricate landscape governing immune responses within the physiology of the head and neck, with a specific emphasis on the concept of cascading defenses. The introduction underscores the paramount significance of comprehending immune responses within this distinctive anatomical context, illuminating the multifaceted nature of the immune system. The initial section scrupulously examines the primary line of defense, elucidating the pivotal role of physical and chemical barriers, including the skin, mucous membranes, and antimicrobial secretions. Transitioning to the subsequent section, the study delves into the realm of innate immune responses, offering insights into the activation mechanisms of phagocytes, the release of inflammatory mediators, and the functioning of the complement system. The third section provides a closer examination of adaptive immune responses, furnishing detailed insights into the activation processes of B and T cells, as well as the establishment of immunological memory. The intricate interplay between the innate and adaptive immune systems is thoroughly explored in the fifth section, with a particular emphasis on the coordination, communication, and feedback loops characterizing their dynamic relationships. To address the unique challenges posed by the distinctive anatomical features of the head and neck, including the presence of specialized immune structures, the sixth section contributes valuable insights. The article further ventures into the realm of immunopathology in head and neck disorders in the subsequent section, shedding light on potential dysregulation, autoimmune implications, and prospective immunotherapy approaches. Section eight extends its focus to future perspectives and research directions, encompassing emerging technologies, therapeutic interventions, and implications for personalized medicine. In conclusion, this study successfully recapitulates the multifaceted narrative surrounding immune responses in head and neck physiology, underscoring the ongoing significance of research in advancing clinical approaches. The dynamic and interconnected nature of immune defenses in this anatomical context serves as a foundation for future investigations and holds promising applications in the field of clinical medicine.

Keywords: Immune Response; Head and Neck; Immunotherapy; Squamous Cell Carcinoma; Physiology

1. Introduction

The cascading defense mechanisms involve a stratified and layered protection strategy, where the primary defense is formed by physical barriers such as the skin and mucous membranes. The epithelial paracellular barrier emerges through the incorporation of intercellular connections called tight junctions. These junctions act as strong protective

* Corresponding author: Jamil Nasrallah

Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

shields, ensuring the safeguarding of both external and internal tissues and organs through intricate layers and protective mechanisms [1,2,3].

Following the initial defenses, the innate immune response demonstrates a sophisticated defensive progression [4,5]. It is critical to the body's defense system [6,7,8]. It extends throughout almost all tissues, involving cells originating from hematopoietic and non-hematopoietic sources. Hematopoietic cell types encompass macrophages, mast cells, neutrophils, eosinophils, and natural killer (NK) cells [6, 9,10].

The cascade continues with the adaptive immune response, activated by the innate immune response [11,12]. While the innate immune response provides an augmented yet not specific immune response, the adaptive one is more sophisticated and exhibits specificity [13]. This adaptive response encompasses various facets of the immune system, including B cells, innate-like T cells, and T helper cells [14,15,16].

The head and neck are exposed to environmental factors, making them susceptible to infections and elevated prevalence of head and neck cancer(HNC) [17,21]. Environmental factors unique to the head and neck region, such as polluted air, dust, tobacco smoke, and climate change, cause allergic rhinitis to occur in the head region [18,22,23]. However, there is a connection between oral care and the onset of head and neck cancer (HNC) [24,25]. For instance, such malignancies come from exposure to human papillomavirus (HPV) infection [18,19,23]. Exposure to the influenza virus can lead to infections in the head and neck region as well [20]. Tumors mentioned stimulate the adaptive immune response, contributing to the effectiveness of immunotherapy [26, 27, 28,29]. A more comprehensive investigation is required to delineate the specific role of senescence-related mechanisms and SASPs, particularly concerning the response to tumor therapy and the patient's immune system status [40]. Nonetheless, the innate immune response governs the regulation of allergic inflammation [30]. Cellular components of the immune system involve a diverse array of cell types, especially white blood cells (macrophages, monocytes, natural killer cells, T and B cells) [31]. Activation occurs in macrophages, mast cells, eosinophils, and NK cells within the framework of innate immunity [6, 9, 10,32]. The latter stimulates adaptive immunity [11, 12, 13, 33, 34]. In its turn activates B and T cells [24, 15,16]. Adding to that, protein signaling such as cytokines secreted fulfill pivotal roles in orchestrating and coordinating immune response [34]. These molecular entities function synergistically to regulate various aspects of the immune system, including communication between immune cells, activation of effector function, and modulation of the overall immune response [35,36]. Lastly, the immune system's pathogen recognition mechanism employs a sophisticated mechanism for identifying a wide array of pathogens by utilizing pattern recognition receptors (PRR) [2, 3, 37, 38]. These receptors recognize distinct molecular patterns associated with various pathogens, enabling the immune system to mount a versatile defense [37,38]. However, few studies mentioned the improved predictive models of the human immune system that are essential for assessing the safety and effectiveness of immunomodulatory drugs and biologics [39].

2. First Line of Defense: Physical and Chemical Barriers

2.1. Skin and mucous membranes as primary physical barriers

The human skin is the biggest organ, making around 15% of the total body weight [41]. It serves as the main chemical and physical defense against insults from the outside [42]. The epidermis, dermis, and subcutaneous fat tissue are the three layers that make up the skin. Divisions of the epidermis comprise: stratum corneum, stratum lucidum, stratum granulosum, and stratum basale. The outermost layer-stratum corneum- that guards against dehydration and pathogen invasion [43]. It is made up of terminally developed keratinocytes called corneocytes, which are embedded in a lipid-rich lamellar matrix to form a barrier resembling "brick and mortar" [44]. Keratinocytes in the stratum basale express toll-like receptors, which are pathogen pattern recognition receptors that, when activated, will lead to an induction of an immune response [45]. Junctional elements such as zonula occludens, desmosomes, adherens, and gap junctions seal the epidermal cells, preventing pathogens from crossing the epidermal barrier and causing water loss. A study done by Furuse et al. demonstrated the importance of claudin-1 in maintaining the epidermal barrier, where mice lacking claudin-1 died shortly after birth due to severe dehydration secondary to barrier weakening [43,46]. In addition, melanocytes present in the epidermis protect the skin from ultraviolet radiation by expressing melanin [45].

Another physical barrier that serves as the first line of defense against pathogens' invasion is the mucous membrane lining internal systems such as the respiratory and digestive tracts [47,48]. The mucosal membrane is considered the main route for host infection by highly pathogenic organisms such as the Ebola virus, the human immunodeficiency virus, and Mycobacterium tuberculosis, which makes it the first defense system encountered by these microorganisms [47]. Similar to the skin, the mucous membrane is characterized by having tight junctions between its epithelial cells and goblet cells interspersed among epithelial cells that secrete mucus, which will be cleared by cilia and peristalsis in the respiratory and digestive systems, respectively [47,48]. The mucosa secreted prevents pathogens from adhering to

the epithelial surface, thus reducing the risk of subsequent infection [49]. Also, mucosal tissue is responsible for the maturation of 80% of the total immune cells in an adult person [47].

2.2. Saliva and mucosal secretions with antimicrobial properties

Human body fluids, including saliva, tears, sweat, and many others, constitute the chemical barrier that protects the corresponding organ. In addition to the presence of proteins with antimicrobial properties known as antimicrobial protein/peptide (AMP), the chemical barrier is composed of other proteins specific to each body fluid [49]. AMPs are cationic molecules contributing to the innate immune response by interfering with cell wall, protein, and nucleic acid synthesis of microbes [50,51]. Examples of AMPs include defensins, cathelicidins, lactoferrin, and lacritin [49]. Defensins and Cathelicidins adhere to bacterial plasma membranes by hydrophobic or electrostatic attraction to form pores and membrane ruptures [52]. The LL-37 type in the cathelicidin family has additional roles in secreting antimicrobial neutrophil extracellular traps, fighting drug-resistant bacteria, and neutralizing their LPS [50]. Another AMP is lactoferrin, which is a glycoprotein present in mucosal secretions [53]. It inflicts a bacteriostatic effect by sequestering iron, a crucial ion for bacterial multiplication [54]. Lysis of iron-free lactoferrin produces lactoferrins, positively charged peptides, that can modify the permeability of microbial membranes and consequently facilitate lysosomal action [53]. In addition to the previously mentioned AMPs, saliva comprises lysozyme and histatins. Lysozyme imposes a bactericidal effect by efficiently disrupting the bacterial cell wall of gram-positive and to a lesser extent gram-negative due to its outer membrane of lipopolysaccharides [55]. Similar to the defensin's, cathelicidin's, and lactoferrin's mode of action, histatins also inhibit the release of pro-inflammatory cytokines from the bacteria by hindering the activity of lipopolysaccharide [56,57]. In the last years, antibiotic resistance has increased rapidly leading to the emersion of superbugs that are multidrug resistant [58]. This necessitated the search for an alternative treatment through which bacteria cannot easily develop resistance. Due to its multiple modes of action that decrease the possibility of acquiring resistance against it, AMPs are the promising candidates. However, limitations such as the expensive, and time-consuming extraction of AMPs make it hard for large-scale production [50].

2.3. Role of commensal microbiota in maintaining barrier integrity

Bacteria, Fungi, and viruses that populate human body surfaces are deemed human microbiota, with the bacteria being the most abundant [42]. The human microbiota inhabits the skin, oral cavity, intestines, and genitourinary system, which aids in sustaining physiological homeostasis [59]. Colonization commensal microbiota on human body surfaces prevents invasion of pathogens by competitively inhibiting pathogenic microbe's adhesion and by secreting antimicrobial molecules known as bacteriocins [55,60]. For example, Staphylococcus epidermidis secretes AMPs that prevent Staphylococcus Aureus and Streptococcus pyogenes colonization and can induce an immune response to form neutrophil extracellular traps [43]. In addition, S. epidermidis maintains skin barrier integrity by providing the host with sphingomyelinase to produce ceramides which are the main components that prevent aging and water loss [61]. The microbiota maintains the physical barrier of the skin by promoting keratinocyte differentiation to form the stratum corneum [2]. To further understand the mechanism behind the previous process, a study was done on murine lacking AHR on keratinocytes that later developed increased skin permeability and susceptibility to infection. Then, they deduced that the microbiota maintains epithelial barrier integrity through keratinocyte AHR signaling [62].

Oral microbiota is the second most diverse bioecological system, with the gut microbiota being the first, where its presence has a direct effect on the health of the oral cavity. It maintains the oral barrier integrity by supporting gingival epithelial cells and by secreting AMPs that enhance gene expression of tight junctions which are crucial for epithelial barrier integrity [63,64].

3. Second Line of Defense: Innate Immune Responses

3.1. Activation of phagocytes (macrophages and neutrophils)

Activation of phagocytes, including macrophages and neutrophils, is a fundamental element within the innate immune response of the head and neck region [64]. Macrophages, key players in immune surveillance, detect tissue damage and identify invading pathogens through pattern recognition receptors [65]. When encountering viral infections, a collaborative effort involving dendritic cells, natural killer cells, macrophages, and neutrophils collectively triggers the innate immune response, effectively combating the infection [66]. To eradicate infections and remove pathogens, phagocyte activation is essential [64]. Through pattern recognition receptors such as Toll-like receptors, these cells recognize pathogen-associated molecular patterns (PAMPs), which trigger the adaptive immune response and amplify inflammation [67]. Phagocyte activation effectively serves as a vital secondary defense mechanism in the innate immune response in the head and neck area, greatly aiding in the containment of infections [64].

3.2. Release of inflammatory mediators and cytokines

In the realm of head and neck squamous cell carcinoma (HNSCC), inflammatory mediators and cytokines hold pivotal roles in orchestrating the immune response [69]. These molecules serve as conduits for communication among immune cells, dictating their reaction to both infectious ailments and cancerous conditions [69]. Notably, research indicates that neoplastic cells release inflammatory cytokines, actively contributing to the genesis and advancement of cancer [70]. Within the landscape of HNSCC, the premalignant environment triggers the production of proinflammatory cytokines, while the subsequent tumor microenvironment becomes less conducive to immune stimulation, resulting in a state of immunosuppression [71]. The HNSCC's ability to disrupt and evade the immune system further augments tumor progression and the likelihood of metastasis [72]. The shifts observed in cytokine profiles within the microenvironment of HNSCC are believed to exert substantial influence over the tumor's aggressiveness, its response to therapeutic interventions, and the development of mechanisms enabling evasion from the immune system [73].

3.3. Complement system and its role in immune cascades

The complement system plays a crucial role in head and neck responses, actively contributing to innate and adaptive immune reactions, functioning as a mediator in combating pathogens and inciting inflammation [74]. Dysregulation in complement activity has been linked to various diseases, ranging from autoimmune conditions to diverse infections . Within the realm of brain injury, the complement system significantly contributes to instigating the inflammatory response, facilitating the recruitment of immune cells, and inflicting damage on the blood-brain barrier [75].

In brain-related conditions, the activation of the complement system can yield diverse outcomes, both protective and detrimental, contingent upon the nature and intensity of the stimuli involved [75,76]. Furthermore, components and regulators within the complement system have been identified as promoters of tumor growth. Interestingly, the complement cascades initiated by therapeutic antibodies targeting tumors substantially influence the response to therapy [76]. This intricate interplay underscores the manifold involvement of the complement system in the dynamics of cancer progression and the responses elicited by treatments [74,75,76].

4. Third Line of Defense: Adaptive Immune Responses

4.1. Activation of B cells and production of antibodies

In the adaptive immune system, particularly in humoral immunity, B cells, also known as B lymphocytes or bursa-derived cells, are fundamental. Humans generate B cells throughout their lives, beginning in the fetal liver during prenatal development and progressing to the bone marrow after birth. B cells develop from hematopoietic stem cells, marking the commencement of their developmental phase [77]. B cells safeguard the body against infections by producing proteins known as antibodies. When the immune system identifies antigens, B cells respond by generating antibodies to combat the intruders [78].

The activation of B cells begins when antigens bind to the B cell receptor (BCR), setting off various signaling pathways that ultimately result in the activation of the B cell [79]. The B-cell antigen receptor transports antigens for processing and presentation on the cell surface. Recognition by helper T cells prompts B cell activation, leading to antibody production. Some microbial antigens can activate B cells directly without T-cell involvement [80].

Mature B cells in peripheral lymphoid organs undergo activation and differentiation into plasma cells through two signals [81]. The first signal, initiated by antigen-bound BCRs, is complemented by a second T cell-dependent or T cell-independent signal [84]. Within germinal centers, B cells undergo processes like somatic hypermutation, affinity maturation, and class switch recombination, ultimately leading to the differentiation of high-affinity B cells into plasma cells for antibody secretion and long-term immune protection [77,81].

Furthermore, plasma cells exist in two classes [82] : short-lived, swiftly exiting ganglia medulla to produce specific IgM antibodies at the antigen entry site, and long-lived, migrating to bone marrow niches for sustained IgG antibody production, supported by SDF-1 and IL-16 [82, 92]. Memory B cells, originating from various sites, express CD27 and undergo isotype changes. Regulatory B cells (Bregs) function as a subset to maintain immune balance, producing anti-inflammatory IL-10 and lacking a definitive marker profile, with CD40-CD154 interaction as an essential activation pathway [82,89,90,93,94].

Regarding antibody production, specialized cells like B cells and plasma cells synthesize specific antibodies in response to antigens [83]. Newly formed B cells initially insert antibodies into their plasma membranes, serving as receptors for antigens, with approximately 10^5 receptors per cell [83,84]. Upon activation, B cells proliferate and differentiate into

effector cells that secrete large amounts of soluble antibodies, matching the unique antigen-binding site of the initial cell-surface receptors. Plasma cells, the mature effector cells, exhibit prolific antibody secretion, with some persisting in the bone marrow for extended periods [84].

Memory B cells are long-lived and quiescent, poised for a rapid antigen response. Derived from antigen activation and T-helper interactions, they coexist with antibody-secreting cells. This memory persists, providing enduring humoral immunity [91,94].

4.2. T cell-mediated responses and cytotoxic activity

T cells, pivotal for active immunity, mature in the thymus, recognizing protein-based antigens on cell surfaces. Classes include CD4+ T cells (helper) supporting immune responses and CD8+ T cells (cytotoxic) targeting infected cells [85]. T cells, crucial for adaptive immunity, circulate between the blood and lymphoid tissues until they encounter specific antigens[82,85,86,88]. Naive T cells activate when antigen-presenting cells, primarily dendritic cells, present antigens, resulting in armed effector T cells with rapid cytotoxic activity [86,87,88]. The differentiation of T cells and the generation of memory T cells contribute to a primary immune response and immunological memory, respectively. The specialized mechanisms of T-cell-mediated cytotoxicity and macrophage activation are integral components of cell-mediated immunity [86]. Regarding Cytotoxic T cells, when presented with a mix of antigen-bearing and non-antigen-bearing target cells, selectively kill only those with specific antigens [82,85,86,87]. This precise targeting results from the focused release of effector molecules at the point of contact, preventing widespread tissue damage and enabling rapid, successive killing of infected cells. Preformed cytotoxic proteins, synthesized during the first encounter with antigen, allow CD8 T cells to execute swift and efficient target cell destruction [87].



Figure 1 This figure shows the stages of TCR activation [88]

The mechanisms of T-cell receptor (TCR) activation involve various models. The aggregation model suggests that pMHC binding induces TCR clustering, activating receptors by trans-autophosphorylation. The segregation model proposes the exclusion of molecules like CD45, favoring CD3 phosphorylation[82,88]. The mechanosensing model suggests membrane sliding generates mechanical force, dissociating CD3 ITAMs for Lck phosphorylation [88]. The allosteric model suggests long-range changes in TCR dynamics transmitted to CD3 by pMHC binding [87,88] . A unified model combines mechanosensing and allostery, where mechanical force induces allosteric changes in TCR, amplifying communication with CD3 following pMHC ligation [85,88].

4.3. Immunological memory and long-term protection

Immunological memory is the immune system's capacity to recognize and respond more effectively upon re-exposure to previously encountered pathogens, ensuring a quicker and stronger response for effective pathogen clearance [89]. B and T cells, key components of the immune system, retain memory of prior encounters, enabling rapid and effective responses to recurring infections for long-term protection [90]. For instance, Memory B cells are long-lived and

quiescent, poised for rapid antigen response. Derived from antigen activation and T-helper interactions, they coexist with antibody-secreting cells. This memory persists, providing enduring humoral immunity [91]. On another hand, Memory T cells, critical for protective immunity, pose challenges in transplantation due to their resistance to immunosuppression. Selective strategies must balance graft survival with maintaining protective immunity against pathogens, considering potential risks such as infections and malignancies [92]. Regarding the fates of these cells, Upon antigen rechallenge in secondary responses, activated memory B cells undergo distinct outcomes [81,84,93]. They either transform into long-lived plasma cells or engage in germinal center (GC) processes, involving population expansion, somatic hypermutation (SHM), and selection [93]. However, Memory T cells, specialized antigen-specific T cells, persist long-term post-infection. Upon reencountering the specific antigen, they rapidly differentiate into numerous effector T cells, ensuring a swift response to previous infections [94].

5. Interplay Between Innate and Adaptive Immune Systems

5.1. Inside the Orchestra: How Cells and Molecules Communicate



Figure 2 Schema showing T cell regulation by neutrophils [100]

Our body's defense operates like a finely tuned orchestra, where two systems - innate and adaptive immunity - seamlessly collaborate to safeguard our cells [95,96]. In addition to myeloid cells including DCs, macrophages, and neutrophils, cytokines are produced to facilitate this interaction [95]. The binding of microbial or self-peptides to the receptors of the myeloid cells (TLR) is the first step in activating innate immunity [97]. Internalized peptides are then expressed by APCs on either MHC-1 or MHC-2 activating CD8+ the or CD4+ respectively [98]. Dendritic cells, the main APCs, recognize danger signals, get activated via the NF-kB pathway [99]. The nature of PAMP encountered by DCs imprints them with the ability to produce specific cytokines and triggers T cell differentiation into Th1 Th2 or Treg. For instance, dsRNA binding to TLR3 or LPS to TL4 activates DC1 producing IL-1 and thus Th1. Parasitic antigen as glycoprotein isolated from Acanthocheilonema viteae induces type 2 DC that activates Th2 [99,102]. In addition, DCs have a role in modifying the tolerance of T-cells in the thymus by inducing Treg which can suppress other T cells, or by producing IL6 rendering T helper cells resistant to this suppression [99]. Neutrophils, the patrolling cells, exhibit a dual role in modulating innate and adaptive immunity [100]. First, hBD-2, defensin secreted by neutrophils, binds to the CC6 chemokine receptor and is chemotactic for both DCs and T memory cells [99]. Neutrophils of the FOXOB3+ population can, under the action of pregnancy hormone, provoke the proliferation of CD4+ Treg by the transfer of FOXO1 protein from neutrophils to naive T cells or through CCL17 production. Moreover, direct signaling between NET of the neutrophils with the TCR can lower the threshold of activation of T lymphocytes which in turn amplify its response to targeted antigen. In contrast, neutrophils can dampen T cells by, firstly, releasing Arg-1 that is stored in their azurophilic

granules or through molecules such as Mac-1 and PD-L1 that are exposed by neutrophils in response to IFN- γ thus suppressing T cells [100] **(fig.2)**. It can also activate the acquired immunity by expressing peptides on their MHC-2 and presenting co-stimulatory molecules [101]. Besides, cytokines secreted by myeloid cells, through the MyD88 signaling, shape the adaptive immune response. Specifically, priming cytokines provoke T cell differentiation into specific Th lineage, IL-18 induces Th1 and IL-33 induces Th2, while other licensing cytokines (IL-1) activate Tem cells [102]. In addition, other cytokines are produced by macrophages to trigger adaptive immunity such as IL-6 which promotes B cell proliferation to plasma cells and activates Tc, inhibits T cell apoptosis and development of Treg, and IL-12 along with IL-18 activates T cell and NK cells [103].

5.2. From Signal to Action: How Antigen-Presenting Cells Guide Lymphocyte Attack

As mentioned before, T lymphocytes, grouped into cytotoxic T cells CTL and T helper cells, are activated by antigens loaded on MHC-1 and MHC-2 expressed by antigen-presenting cells APCs [98]. DCs, platelets, macrophages, neutrophils, and B lymphocytes are divided into professional APCs including DCs, B cells, and macrophages, and non-professional APCs which are other myeloid cells platelets and neutrophils [104]. Beginning with DCs activation of T cells occurs through 4 steps. The first signal is by the interaction of the TCR with MHC and the specific antigen establishing antigen specificity, then co-stimulatory molecules, such as B7-1 B7-2 expressed on APCs that bind to CD28 CTLA-4 on the T cell surface, provide co-signaling for T-cells to respond. This stimulates the CD4+ T cells to differentiate into Th1, Th2, or Treg, and to produce homing receptors directing them to migrate to their assigned tissue [97,99]. On the other hand, antigen presentation by macrophages is not yet well understood, however, pro-inflammatory macrophages can express self-proteins in their MHC1-activating memory CD8+ [105]. For the B cells, endocytosed exogenous peptides are delivered to the ER by TAP, where they are further processed by ERAP to load on the MHC molecule's cell surface intended for presentation. The conventional MHC II loading route is used for antigen processing when BCR is engaged in antigen detection and capture. The clonally unique BCR expressed by B cells enables them to detect antigens even in minuscule amounts. Furthermore, higher affinity antigens are present in T cells more effectively and produce stronger, faster BCR signaling. [104]. Besides, platelets are considered non-potent APCs, yet they can activate T cells via PMHC1, by which their expression on the platelet's membrane increases during inflammation [106]. Finally, neutrophils boost adaptive immunity by carrying antigens to the DCs and regulating macrophages, as well as expressing MHC-2 and co-stimulatory CD-80, CD-83, and CD-86 [100,101]. A study done on the immune response to Mycobacterium Tb demonstrated that DCs expressing antigens carried by neutrophils have more proper migration to lymph nodes than other DCs loading endocytosed peptides [100].

5.3. The Immune System's Amplifier: Unveiling Feedback Loops of Defense

T lymphocytes activated by binding of the TCR to their corresponding MHC and CD28 to the co-stimulatory molecule CD80/CD86 will express on its membrane CD40L which adhere to CD40 on the active DCs resulting in further expression of CD80, CD86, OX40L, and ICOSL triggering T cell activation and expansion [97,106]. Activated T cells will in turn stimulate B cells either by synapsing or secreting IL-4 IL-5 [106]. As part of their function, B cells through presenting antigens on their MHC and secreting CCL17 and CCL22 , create positive feedback rendering T cells active [104]. In the way of boosting the immune response, activated T lymphocytes secrete cytokines and other molecules that act on the first line of defense cells. Th1 cells primarily secrete IFN-γ which amplifies the phagocytic activity of macrophages. In addition, activated Th2 cells release IL-4 upregulating mononuclear phagocytes (PMNs) as well as releasing pro-inflammatory mediators including IL-6, GM-CSF, and VCAM-I adhesion molecules [107]. Playing back and forth adaptive immunity amplifies the action of the APCs by TNFRSF signals manifested by T cells [102]. Furthermore, boosting the primary response, antibodies secreted by plasma cells can recruit phagocytes for pathogen internalization and representation to the TCR [99].

6. Head and Neck Physiology in the Context of Immune Responses

6.1. Unique challenges posed by the anatomical features of the head and neck

The head and neck region's anatomical form offers a unique paradigm for immune system functions, requiring sophisticated immunological approaches to negotiate the inherent complexity while safeguarding the integrity and functionality of vital organs [108].

The neurological proximity of the head and neck region to the central nervous system, particularly the brain protected by the blood-brain barrier (BBB), demands a highly regulated immune response to maintain homeostasis [109-111]. The BBB plays a critical role in preventing immune cell infiltration into brain tissue, necessitating a delicate balance to avoid neuroinflammation. Additionally, effective clearance of local infections is essential to prevent the risk of ascending infections that could breach the blood-brain barrier, thereby preserving the stability of the central nervous system [109-

111]. The intricate vascular architecture of the head and neck, encompassing vital cerebral and facial blood veins, requires a well-tuned immune response to navigate the complexities of the vascular system [112]. This response is crucial for preventing systemic inflammation that can compromise cerebral perfusion or cause vascular injury. The endothelial cells lining these arteries play a vital role in localized immune monitoring and response by regulating leukocyte trafficking and inflammatory reactions [113,114].



Figure 3 Arteries of the Head and Neck- External Carotid, Internal Jugular Vein, External Maxillary [114]



Figure 4 Jugular Veins and Arteries of the Neck [116]

In the head and neck region, immune responses must be meticulously regulated to prevent collateral damage to sensory organs and nerve pathways, with the aim of minimizing the risk of potential sensory impairment or neuropathic conditions [117,118]. Acting as primary entry points, the oral, nasal, and ocular pathways require a distinctive mucosal immunity strategy involving the production of secretory IgA, mucosal-associated lymphoid tissue (MALT), and various innate defense mechanisms. This specialized mucosal immunity must be vigilant against a broad spectrum of infections while preserving mucosal integrity, emphasizing the importance of avoiding aggressive immune reactions that could impair physiological processes [121,122,123]. Achieving a controlled and limited immune response in these areas is essential for maintaining the functionality of sensory organs and nerve pathways, while effectively defending against potential pathogens. The head and neck region features a complex lymphatic drainage system, comprising a network of lymph nodes and lymphatic veins, which is essential for efficient immune monitoring. This system facilitates the mobilization of antigen-presenting cells to the lymph nodes, serving as the starting point for adaptive immune responses and playing a crucial role in coordinating targeted immune responses and preventing the spread of infections throughout the body [124,125,126]. Simultaneously, continual exposure of the head and neck to external agents necessitates an adaptable immune interface to distinguish between harmless and harmful antigens. This region encounters a myriad of allergens and contaminants, requiring a finely tuned immune system to prevent dysregulation that could lead to hypersensitivity reactions and persistent inflammatory states. The distinct anatomical and physiological features of the head and neck, including its proximity to the central nervous system, extensive vascular and lymphatic networks, density of sensory organs, and frequent exposure to environmental chemicals, create a dynamic environment that demands a highly specialized, flexible, and regulated immune system [112,115,120,123,124]. Understanding these complexities is crucial for the development of clinical approaches for the diagnosis, treatment, and prevention of head and neck diseases, particularly those of immunological origin [112,115,124].

6.2. Specialized immune structures such as tonsils and lymph nodes

Tonsils, a collection of lymphoid tissues situated in the throat's pharyngeal area, are vital for the immune system, especially in reacting to pathogens that are breathed in or ingested [128,131,132]. In humans, there are three types of tonsils: palatine tonsils, pharyngeal tonsils (often called adenoid tonsils), and lingual tonsils [133]. The structure of the tonsils is integral to their role in the immune system, primarily in triggering immune responses to pathogens entering through the mouth or nasal passages [133]. Anatomically speaking, the palatine tonsils are positioned at the back of the throat on each side of the oropharynx, they are nestled between the Palatoglossal and Palatopharyngeal arches [108,133].



Figure 5 Anatomy Location of Palatine Tonsil [108]

Deep into the tonsil parenchyma, these crypts are home to various immune cells and bacteria [133]. The tonsil's structure is mainly composed of lymphoid tissue, which is a form of connective tissue that consists of a lot of lymphocytes [134]. These lymphocytes are largely B-cells and T-cells, which are essential components of the immunological response [132,133]. Germinal centers are active locations of B-cell proliferation, maturation, and differentiation within lymphoid tissue [132,133]. These sites are critical for the adaptive immune response because they enable antibody synthesis [133]. The tonsil surface is lined by stratified squamous epithelium [136]. This epithelium continues into the crypts, where it comes into contact with a variety of immune cells [135]. The tonsils are vascularized by external carotid artery branches and have lymphatic drainage that connects them to the cervical lymph nodes [133]. The structure of the tonsils equips them to effectively perform their function as part of the immune system [132,133]. They act as a first line of defense, trapping and processing pathogens and stimulating an immune response [132,133,136]. When B cells in the tonsils come into contact with a pathogen or its antigens, they can transform into plasma cells that generate antibodies specific to that infection [108,132,136]. It also leads to the development of T and B-memory cells [117]. The tonsils protect against infections in the respiratory and gastrointestinal tracts by responding to pathogens entering through the mouth and nose [132,133].

The lymph nodes in the head and neck region play an important role in the body's immune surveillance and response, especially in filtering lymphatic fluid and housing immune cells capable of attacking infections [115,138]. These lymph

nodes are part of the larger lymphatic system, which is essential for both the circulatory and immunological systems [137,138].



Figure 6 Lymph nodes of the head and Neck: Posterior auricular glands, occipital glands, Superficial cervical glands, Superior deep cervical glands, Inferior deep cervical glands, Submental glands, Submaxillary glands, Supramandibular glands, Buccinator glands, Parotid glands, Maxillary glands [116]

6.2.1. Immunological Role and Function of Lymph Node

Lymph nodes in the head and neck region play crucial roles in both immune regulation and the detection of diseases. Acting as filters, they capture infections, foreign particles, and cancer cells, effectively screening lymph before it circulates back into the venous system [123,124,137]. These nodes accommodate a diverse population of immune cells, including lymphocytes, macrophages, and dendritic cells, essential for initiating and regulating immunological responses [119,137,140,141,142]. Within the lymph nodes, B cells differentiate into plasma cells producing antibodies, while T cells can activate to support other immune cells or directly eliminate infected cells, their interaction with dendritic cell antigens being vital for adaptive immune responses [119,140,141,142]. Certain lymph nodes host germinal centers where B cells undergo multiplication, differentiation, and antibody gene mutations, generating antibodies with high affinity [142]. In the field of oncology, head and neck lymph nodes serve as significant sentinel nodes for tumor spread, influencing cancer staging and prognosis based on their condition [144]. Comprehensive knowledge of lymphatic drainage patterns in the head and neck is crucial for the identification and management of infections, inflammatory disorders, and malignancies, with the enlargement of specific nodes offering valuable insights into underlying conditions [144].



Figure 7 Lymph nodes of the neck; Posterior view, Afferent vessel to deep cervical glands, Afferent vessels of retropharyngeal glands, Retropharyngeal glands, Glandular nodule, Gland of deep cervical chain, Efferent vessels of retropharyngeal glands [139]

6.3. Immunological considerations in oral and respiratory health

The oral and respiratory systems in the head and neck region engage continuously with the external environment, requiring sophisticated immune defenses for the preservation of health and prevention of diseases [119,125]. The oral cavity, hosting a diverse microbiota, employs intricate immunobiological mechanisms for ongoing immune surveillance. Salivary glands actively release antimicrobial peptides and immunoglobulins, notably IgA, serving as a primary defense against infections. Mucosa-associated lymphoid tissue (MALT) in the oral mucosa is crucial for detecting antigens and initiating local immune responses, densely populated with immune cells like dendritic cells, macrophages, and lymphocytes. These cells work collaboratively to protect oral mucosal immunity and inhibit the overgrowth of pathogens [140,142,146,147]. In the respiratory tract, comprising upper and lower airways, a mucociliary epithelium acts as a physical barrier against inhaled microorganisms. Mucociliary clearance, a key innate defense mechanism, involves coordinated actions of ciliated epithelial cells and mucus formation. Additionally, alveolar macrophages in the lower respiratory tract play a central role in monitoring the pulmonary environment, participating in phagocytosis of infections and presenting antigens to initiate adaptive immune responses [119,122,140,148,149,150]. Microbial surveillance and immune tolerance mechanisms play crucial roles in the oral and respiratory systems of the head and neck, as microbes are constantly present in these areas. The immune system must distinguish between commensal flora and pathogenic species, guided by intricate immunological tolerance and monitoring mechanisms [145,150]. Imbalances in this delicate equilibrium can lead to dysbiosis and pathogenic overgrowth, contributing to conditions like periodontal disease and chronic respiratory ailments [150,151,152]. Furthermore, the immune system in the head and neck is susceptible to dysregulated responses, as evidenced in allergic and autoimmune reactions [153,154,155]. Hypersensitivity to environmental allergens triggers excessive immunological responses characterized by IgE-mediated mast cell degranulation and production of inflammatory mediators, manifesting in conditions such as allergic rhinitis and asthma [154,155]. Autoimmune illnesses, such as Sjögren's syndrome, involve abnormal immune reactions against salivary and lacrimal glands, impacting oral and ocular health [153]. The intricate interplay between microbial surveillance, immune tolerance, and susceptibility to dysregulated responses highlights the importance of maintaining a delicate balance in the overall health of the head and neck immune system. The mucosal immune system in the oral and respiratory tracts plays a pivotal role in preventing infections and in influencing disease progression [121,122,146]. A combination of innate and adaptive immune components, including barrier function, cellular immunity, and humoral responses, is essential to effectively respond to infectious challenges and maintain homeostasis [119,140,141,143]. Disruptions in this intricate immunological network can increase the susceptibility to infections and contribute to the

development of chronic inflammatory diseases [144,153,154]. Understanding the immunobiology of the oral and respiratory tracts is crucial for the development of targeted therapeutic approaches to treat and prevent diseases affecting these vital organs [119,142]. This comprehension is fundamental for advancing medical interventions that specifically address the unique immunological dynamics of oral and respiratory mucosal environments.

7. Immunopathology in Head and Neck Disorders

7.1. Dysregulation of immune responses in inflammatory conditions

The mechanisms of immune dysregulation in head and neck inflammatory conditions encompass a range of processes, including manipulating immunogenicity, producing immunosuppressive molecules, fostering immunomodulatory cell types, disrupting antigen presentation, altering cytokine balance, and disturbing the equilibrium of immune checkpoints and costimulatory molecules [161,172,173,174,175,176]. Transitioning to specific inflammatory conditions, in Graves' disease (GD), there is an aberrant expression of HLA class II antigens, mononuclear cell infiltration, and increased adhesion molecule and vascular endothelial cell expression, implying the involvement of cytokines and immune regulation in its pathogenesis [172,173]. Turning attention to head and neck dermatitis (HND), this condition involves reduced ceramide levels that contribute to skin barrier dysfunction, facilitating Malassezia furfur proliferation and inducing pro-inflammatory cytokine production [174].

In the context of cancers, such as squamous cell carcinoma of the head and neck (HNSCC), complex interactions unfold between cancer stem cells (CSCs) and immune cells within the tumor microenvironment. These CSCs employ various strategies, including cell surface receptors, secreted products, ligands, and genetic regulation, to suppress the immune response [175]. Moreover, head and neck squamous cell carcinoma (HNSCC) creates an immunosuppressive milieu, allowing the tumor to elude immune responses. This involves the dysregulation of immunogenicity, production of immunosuppressive mediators, and promotion of immunomodulatory cell types [161,176].



Figure 8 Oral and head and neck cancer stem cells (CSCs) utilize various mechanisms for immune escape, such as elevated PD-L1 in ALDHhigh-CSCs recruiting suppressive MDSCs and CD276 and AP-1-expressing CSCs establishing a positive feedback loop to suppress CD8+ T cells, indicating the versatility of CSCs in activating multiple immune avoidance mechanisms [174]

7.2. Autoimmune implications in head and neck diseases

In the exploration of the potential link between autoimmune diseases and the onset of head and neck cancers, it becomes evident that vigilant monitoring by healthcare providers is essential for the early detection of signs or symptoms indicative of malignancies within this specific region. Recognizing these associations proves critical for prompt diagnosis and effective management, thereby facilitating comprehensive care for individuals navigating the complex intersection of autoimmune conditions and heightened susceptibility to head and neck cancers [162,163,170,171]. There's a connection between Ménière's disease, an autoimmune disease, and thyroid conditions, including goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis, as indicated by various studies. In a nested case-control study carried out in Korea, individuals with Ménière's disease exhibited elevated instances of goiter, hypothyroidism, thyroiditis, hyperthyroidism, and autoimmune thyroiditis in comparison to the control group [170]. Transitioning granulomatosis with polyangiitis, a rare autoimmune disorder, frequently presents with head and neck involvement, particularly sinonasal disease [162]. Additionally, the head and neck region can be affected by

Immunoglobulin G4-related disease (IgG4-RD), establishing a plausible connection between IgG4-RD and malignancies in this anatomical area [163]. Notably, there's an association between nasal polyps and nine autoimmune conditions across various genders [171].



Figure 9 A schematic representation of a pathogenetic pathway in the development of head and neck dermatitis (HND) in atopic dermatitis (AD) patients, wherein reduced ceramide levels lead to Malassezia furfur proliferation, prompting keratinocytes to release Th2 cytokines and vascular endothelial growth factor (VEGF), triggering dermal endothelial cells to produce cytokines, ultimately intensifying eczematous inflammation and tissue remodeling [173]



Figure 10 Granulomatosis with polyangiitis (GPA) manifests as severe sinonasal involvement, evident in a 46-year-old female patient through axial, sagittal, and coronal CT images showcasing near-total destruction of the nasal septum and turbinates, accompanied by complete collapse of nasal soft tissues, and another patient exhibiting complete destruction of midline sinonasal structures, resembling an autorhinectomy appearance on CT scans [162]



Figure 11 The clinicopathological findings in this case involve a well-defined, slightly enhanced soft-tissue-density mass with calcification in the right submandibular gland, an enlarged pancreas seen on axial contrast-enhanced CT, PET scans indicating accumulation in the right submandibular gland along with the pancreas, prostate, and kidney, and histological examination revealing comedo-type necrosis, atrophic glands surrounded by fibrosis, and positive IgG4 staining of plasma cells in the submandibular gland tissue [163]

7.3. Immunotherapy approaches for managing immune-related disorders



Figure 12 The immune escape pathways in head and neck squamous cell carcinoma (HNSCC) and outlines dysfunctional components like NK cells, dendritic cells, and T cells, with proposed models illustrating the reversal of immune escape during monoclonal antibody therapy, emphasizing the role of cetuximab-mediated NK cell-dependent tumor cell lysis and the impact of regulatory T cells on immune activity [161]

Moving into the domain of head and neck cancer treatment, immunotherapy, particularly involving immune checkpoint inhibitors, emerges as a promising avenue with the potential to improve overall survival and enhance quality of life. Ongoing investigations delve into neoadjuvant strategies and considerations for antibiotic effects on immunotherapy efficacy [161,164,165,166,167,168,169]. Exploring the broader spectrum of immunotherapy for head and neck cancer (HNC), this approach holds promise, utilizing immune checkpoint inhibitors (ICI) either as monotherapy or in combination with chemotherapy (QT) to augment overall survival (OS) and enhance patients' quality of life [164]. Further exploration includes ongoing investigations into neoadjuvant immunotherapy before surgery and immunochemoradiotherapy for locally advanced HNC [165]. Specifically within the context of head and neck squamous cell carcinoma (HNSCC), immunotherapy acts to counter immune dysregulation, with PD-1 inhibitors showing significant survival benefits in recurrent/metastatic (R/M) HNSCC [166]. Significant advancements include neoadjuvant immunochemotherapy demonstrating advantages in HNSCC patients, while biomarkers such as PD-L1 and IGF play pivotal roles in upregulating PD-L1 and IGF in HNSCC [167,168]. Examining the impact of antibiotics during immunotherapy, their usage has been associated with reduced effectiveness in oral cancer, potentially due to antibiotic-induced alterations in the gut microbiome [169].

8. Future Perspectives and Research Directions

8.1. Emerging technologies in immunology research for head and neck physiology

A myriad of emerging technologies is reshaping our understanding and application of immune system dynamics. Some of these technologies considered here are omics technologies, immune and antibodies engineering, and engineered nanoparticles. Omics encompass many areas of research such as genomics, transcriptomics, proteomics, metabolomics, etc [177] … Omics play a crucial role in unveiling intricate characteristics and investigating the development of various disorders and illnesses. Moreover, they can identify new molecular mechanisms and biomarkers, thereby contributing to advanced insights in immunology research [206]. Some of the promising tools and methods used in these domains are T-cell receptor sequencing (TCR-Seq), and single cell ribonucleic acid sequencing (ScRNA-Seq) [178,179,180,181,182].

Immunological engineering constitutes a novel field that employs engineering principles and tools to explore and manipulate the immune system. Research in immunoengineering ranges from molecular dimensions to population scales, playing a vital role in both health and disease contexts [183]. This includes engineering biomimetic materials that imitate the various conditions in living in vivo, designing biomaterials that induce immune tolerance, and enhancing immunotherapies and some drugs permeability [183,184,185]. Not to forget that immunoengineering encompasses the design of new vaccines, and engineered antibodies that optimize immunology research [183,186].

In addition, engineered nanoparticles not only have great applications in therapies such as maneuvering the innate immune system, and having immunosuppressive and anti-inflammatory properties, they are used for analysis and imaging [187,188,215].

8.2. Potential Therapeutic Interventions Based on a Deeper Understanding of Cascading Defense

8.2.1. Trained Immunity

Trained immunity refers to the enduring functional reprogramming of innate immune cells triggered by external or internal factors. This results in a modified response to a second challenge after reverting to a non-activated state. The secondary reaction to the upcoming non-specific stimulus may be adjusted, causing the cells to respond more or less intensely than in the initial response, offering responses tailored to context and time [189]. The orchestration of immune memory is primarily controlled by epigenetic and metabolic reprogramming. While distinct sets of epigenetic and metabolic enzymes mediate these mechanisms, there exist robust significant and mutual correlations between metabolic modifications and epigenetic shifts [191,192,193]. Controlling trained immunity presents a potent therapeutic approach across various disease scenarios [189,190]. For instance, modifying gene expression through targeting epigenetic events proves to be an advantageous approach in regulating immune responses for specific autoimmune diseases and conditions characterized by immune suppression [192]. Also, inducing trained immunity might be favorable for supporting specific treatments such as cancer therapies or addressing immune dysfunction linked to sepsis. Promising therapeutic possibilities also include restraining an excessively trained innate immune state in chronic inflammatory conditions or averting potentially harmful trained immunity in organ transplantation [189,190]. In addition, utilizing trained immunity-based vaccines (TIbVs) as immunostimulants could serve as a novel immunotherapeutic strategy against both noninfectious and infectious immune-related disorders caused by endogenous pathogens [192].

8.2.2. Universal Chimeric Antigen Receptor T Cell Therapy

The engineering of immune cells for adoptive T cell immunotherapy, particularly the application of chimeric antigen receptor (CAR) T cells, is demonstrating significant potential in clinical settings [193]. CARs are artificial receptors constructed with an antibody-like extracellular portion fused to a transmembrane domain and incorporating T Lymphocyte cell activation and costimulatory elements. CARs confer upon T cells specificity to a target antigen in an MHC-independent manner. This leads to the initiation of cytotoxicity, cytokine production, proliferation, and, in certain scenarios, the establishment of enduring memory [194]. At present, there is a prominent focus on universal CAR-T (UCAR-T) cell therapy, anticipated to surmount existing challenges [195]. There have been more than hundreds of preclinical and clinical trials of allogeneic CAR-T cell therapy worldwide [195,196,197]. Although utilizing UCAR-T therapy with cells from healthy individuals offers several advantages, it is noteworthy to mention that further research and concerted efforts are required [198].

8.3. Implications for Personalized Medicine in the Context of Immune Responses

8.3.1. Machine Learning (ML), and Artificial Intelligence (AI):

Personalized medicine seeks to customize healthcare approaches for individualized efficacy by combining large datasets with individual genetic, functional, and environmental variables [199]. In light of the growing amount of accessible data, predictive models are being used in Electronic Health Records (EHRs) to manage and correlate the various patient profiles. With the help of the patient's genetic information and medical history, machine learning algorithms can quickly sort through and learn from the wide variety of available treatments, recommending the one that will work best for them [200]. This enhances the process's productivity and efficiency. Additionally, machine learning classification algorithms are capable of operating at minuscule scales. These can foretell which genotypes, and whether they exist, will result in an adverse prognosis. They are even able to identify phenotypes and categorize them further to forecast the probability and level of severity of a certain illness [200,201]. Furthermore, genotypes that have the potential to yield resistant phenotypes can be identified by ML algorithms. This proves to be highly advantageous, especially in scenarios where resistance is involved, as various factors contribute to the level of resistance, each with its specific significance. Image-based phenotype detection algorithms also can examine a broader range of phenotypes within a significantly shorter timeframe. Consequently, these algorithms can be utilized to ascertain the potential types of immune responses, such as macrophage activation and lymphocyte infiltration [202]. It is worth mentioning that AI algorithms are frequently involved in immunopeptidome identification, a field of immunology that is engaged in personalized vaccines [200]. Besides, ML and AI are progressively utilized to categorize transcriptomic, proteomic, and metabolomic information for biomarker screening, constructing prognostic models, and determining the appropriate patients for specific treatments [177].

8.3.2. Biomarkers Identification:

Biomarkers are essential in precision medicine as they offer details about diverse diseases resulting from immune responses, and assist in precise diagnoses. Various biological markers - which can be measured in serum, bodily fluids, and exhaled air - such as pro-inflammatory mediators, eicosanoid molecules, and microRNA molecules -serve a valuable purpose in diagnosing and monitoring immune disorders in a personalized manner. For example, sputum eosinophils, serum periostin, and exhaled nitric oxide are among the recognized biomarkers that show potential in identifying type 2 allergic diseases [203]. The recognition of predictive biomarkers not only assists in diagnosing a condition but also plays a crucial role in determining suitable personalized treatments and evaluating the efficacy of the selected therapy [204,205]. Moreover, microbiome diversity and epithelial barrier integrity are crucial biological markers where a strong correlation between an imbalance in the microbiome and impairment of the epithelial barrier is likewise associated with various chronic inflammatory conditions, such as allergies, metabolic disorders, and autoimmune illnesses. Hence, microbiome profiling could prove advantageous in clinical trials focused on developing personalized biotherapeutic treatments [208,209,210].

8.3.3. Genetic Editing

The significant genetic diversity demonstrates the vast range of variations between individuals, particularly in susceptibility to diseases and their existence, as well as reactions to interventions. Gene editing technologies have the potential to modify particular portions of the genome, opening up new possibilities for accurately repairing faulty genes [211].The CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats) system is a revolutionary approach to gene editing and a promising tool in precision medicine.The CRISPR/Cas9 cell screens and animal models can demonstrate significant potential in identifying drug targets, cancer, and immune biomarkers, enabling more precise treatments for distinct diseases such as cancer [212,213]. The CRISPR/Cas9 system can be used to inhibit or enhance the expression of inflammatory molecules, e.g. cytokines, by targeting responsible genes. Furthermore, this editing tool

provides distinct therapies in autoimmune disorders such as the production of genetically edited mesenchymal stem cells (MSC) and induced pluripotent stem cells (iPSC) [214,216].

9. Conclusion

In conclusion, the intricate interplay between the immune system and the unique anatomy of the head and neck necessitates sophisticated defense mechanisms to protect vital structures while addressing environmental challenges. The cascading defense strategy, involving both innate and adaptive immunity, reflects the complexity required to combat various threats.

Understanding these immune responses is crucial in light of potential risks from environmental factors, infections, and diseases like head and neck cancers. The multifaceted nature of immune responses, from physical barriers to coordinated activation of innate and adaptive components, is essential for comprehensive defense.

Examining specialized immune structures, such as tonsils and lymph nodes, underscores their pivotal roles in orchestrating region-specific immune responses. Tonsils serve as frontline defenders against pathogens entering the respiratory and gastrointestinal tracts, while lymph nodes strategically filter and house immune cells for localized surveillance.

Acquiring a nuanced understanding of these complexities is imperative for developing targeted clinical approaches to diagnose, treat, and prevent head and neck diseases, particularly those with immunological origins. The integration of environmental influences emphasizes the need for adaptive immune interfaces capable of discerning between harmless and harmful agents. Navigating this intricate landscape underscores the vital role of the immune system's specialization, flexibility, and regulation in maintaining health and preserving the delicate balance between protection and potential collateral damage in the head and neck region.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Capaldo CT, Powell DN, Kalman D. Layered defense: how mucus and tight junctions seal the intestinal barrier. J Mol Med [Internet]. 2017, 95(9):927–34. Available from: http://dx.doi.org/10.1007/s00109-017-1557-x

[2] Harris-Tryon TA, Grice EA. Microbiota and maintenance of skin barrier function. Science [Internet]. 2022, 376(6596):940–5. Available from: http://dx.doi.org/10.1126/science.abo0693

[3] Saez A, Herrero-Fernandez B, Gomez-Bris R, Sánchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of inflammatory bowel disease: Innate immune system. Int J Mol Sci [Internet]. 2023, 24(2):1526. Available from: http://dx.doi.org/10.3390/ijms24021526

[4] Gustafsson JK, Johansson MEV. The role of goblet cells and mucus in intestinal homeostasis. Nat Rev Gastroenterol Hepatol [Internet]. 2022, 19(12):785–803. Available from: http://dx.doi.org/10.1038/s41575-022-00675-x

[5] Harms AS, Ferreira SA, Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson's disease. Acta Neuropathol [Internet]. 2021, 141(4):527–45. Available from: http://dx.doi.org/10.1007/s00401-021-02268-5

[6] Kaur BP, Secord E. Innate immunity. Immunol Allergy Clin North Am [Internet]. 2021, 41(4):535–41. Available from: http://dx.doi.org/10.1016/j.iac.2021.07.003

[7] Rousset F. Innate immunity: the bacterial connection. Trends Immunol [Internet]. 2023, 44(12):945–53. Available from: http://dx.doi.org/10.1016/j.it.2023.10.001

[8] De Marco Castro E, Calder PC, Roche HM. B-1,3/1,6-glucans and immunity: State of the art and future directions. Mol Nutr Food Res [Internet]. 2021, 65(1). Available from: http://dx.doi.org/10.1002/mnfr.201901071

[9] Chen J, Gao L, Wu X, Fan Y, Liu M, Peng L, et al. BCG-induced trained immunity: history, mechanisms and potential applications. J Transl Med [Internet]. 2023, 21(1). Available from: http://dx.doi.org/10.1186/s12967-023-03944-8

[10] von Pein JB, Stocks CJ, Schembri MA, Kapetanovic R, Sweet MJ. An alloy of zinc and innate immunity: Galvanising host defence against infection. Cell Microbiol [Internet]. 2021, 23(1). Available from: http://dx.doi.org/10.1111/cmi.13268

[11] Bunte K, Beikler T. Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci [Internet]. 2019, 20(14):3394. Available from: http://dx.doi.org/10.3390/ijms20143394

[12] Sun L, Wang X, Saredy J, Yuan Z, Yang X, Wang H. Innate-adaptive immunity interplay and redox regulation in immune response. Redox Biol [Internet]. 2020, 37(101759):101759. Available from: http://dx.doi.org/10.1016/j.redox.2020.101759

[13] Netea MG, Schlitzer A, Placek K, Joosten LAB, Schultze JL. Innate and adaptive immune memory: An evolutionary continuum in the host's response to pathogens. Cell Host Microbe [Internet]. 2019, 25(1):13–26. Available from: http://dx.doi.org/10.1016/j.chom.2018.12.006

[14] Ansaldo E, Farley TK, Belkaid Y. Control of immunity by the Microbiota. Annu Rev Immunol [Internet]. 2021, 39(1):449–79. Available from: http://dx.doi.org/10.1146/annurev-immunol-093019-112348

[15] Lee H-G, Cho M-J, Choi J-M. Bystander CD4+ T cells: crossroads between innate and adaptive immunity. Exp Mol Med [Internet]. 2020, 52(8):1255–63. Available from: http://dx.doi.org/10.1038/s12276-020-00486-7

[16] Chapman NM, Chi H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity [Internet]. 2022, 55(1):14–30. Available from: http://dx.doi.org/10.1016/j.immuni.2021.12.012

[17] Vučičević Boras V, Fučić A, Baranović S, Blivajs I, Milenović M, Bišof V, et al. Environmental and behavioural head and neck cancer risk factors. Cent Eur J Public Health [Internet]. 2019, 27(2):106–9. Available from: http://dx.doi.org/10.21101/cejph.a5565

[18] Tumban E. A current update on human Papillomavirus-associated head and neck cancers. Viruses [Internet]. 2019, 11(10):922. Available from: http://dx.doi.org/10.3390/v11100922

[19] Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Br J Cancer [Internet]. 2020, 122(3):306–14. Available from: http://dx.doi.org/10.1038/s41416-019-0602-7

[20] Foster CE, Kaplan SL. Complicated head and neck infections following influenza virus infection in children. Pediatr Infect Dis J [Internet]. 2019, 38(9):e226–8. Available from: http://dx.doi.org/10.1097/inf.0000000000002294

[21] Tasoulas J, Srivastava S, Xu X, Tarasova V, Maniakas A, Karreth FA, et al. Genetically engineered mouse models of head and neck cancers. Oncogene [Internet]. 2023, 42(35):2593–609. Available from: http://dx.doi.org/10.1038/s41388-023-02783-7

[22] Eguiluz-Gracia I, Mathioudakis AG, Bartel S, Vijverberg SJH, Fuertes E, Comberiati P, et al. The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma. Allergy [Internet]. 2020, 75(9):2170–84. Available from: http://dx.doi.org/10.1111/all.14177

[23] Vallianou NG, Evangelopoulos A, Kounatidis D, Panagopoulos F, Geladari E, Karampela I, et al. Immunotherapy in head and neck cancer: Where do we stand? Curr Oncol Rep [Internet]. 2023, 25(8):897–912. Available from: http://dx.doi.org/10.1007/s11912-023-01425-1

[24] Bai X, Cui C, Yin J, Li H, Gong Q, Wei B, et al. The association between oral hygiene and head and neck cancer: a meta-analysis. Acta Odontol Scand [Internet]. 2023, 81(5):374–95. Available from: http://dx.doi.org/10.1080/00016357.2022.2158129

[25] Lee H-J, Han D-H, Kim J-H, Wu H-G. The effect of comprehensive oral care program on oral health and quality of life in patients undergoing radiotherapy for head and neck cancer: A quasi-experimental case-control study. Medicine (Baltimore) [Internet]. 2021, 100(16):e25540. Available from: http://dx.doi.org/10.1097/md.0000000000025540

[26] He H, Hao Y, Fan Y, Li B, Cheng L. The interaction between innate immunity and oral microbiota in oral diseases. Expert Rev Clin Immunol [Internet]. 2023, 19(4):405–15. Available from: http://dx.doi.org/10.1080/1744666x.2023.2182291

[27] Lin D, Yang L, Wen L, Lu H, Chen Q, Wang Z. Crosstalk between the oral microbiota, mucosal immunity, and the epithelial barrier regulates oral mucosal disease pathogenesis. Mucosal Immunol [Internet]. 2021, 14(6):1247–58. Available from: http://dx.doi.org/10.1038/s41385-021-00413-7

[28] Wang X, Wu S, Liu F, Ke D, Wang X, Pan D, et al. An immunogenic cell death-related classification predicts prognosis and response to immunotherapy in head and neck squamous cell carcinoma. Front Immunol [Internet]. 2021, 12. Available from: http://dx.doi.org/10.3389/fimmu.2021.781466

[29] Maiorino L, Daßler-Plenker J, Sun L, Egeblad M. Innate immunity and cancer pathophysiology. Annu Rev Pathol [Internet]. 2022, 17(1):425–57. Available from: http://dx.doi.org/10.1146/annurev-pathmechdis-032221-115501

[30] Cao Y, Li Y, Wang X, Liu S, Zhang Y, Liu G, et al. Dopamine inhibits group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity. Immunity [Internet]. 2023, 56(2):320-335.e9. Available from: http://dx.doi.org/10.1016/j.immuni.2022.12.017

[31] Suo C, Dann E, Goh I, Jardine L, Kleshchevnikov V, Park J-E, et al. Mapping the developing human immune system across organs. Science [Internet]. 2022, 376(6597). Available from: http://dx.doi.org/10.1126/science.abo0510

[32] Ni S, Yuan Y, Kuang Y, Li X. Iron metabolism and immune regulation. Front Immunol [Internet]. 2022, 13. Available from: http://dx.doi.org/10.3389/fimmu.2022.816282

[33] Domínguez-Andrés J, dos Santos JC, Bekkering S, Mulder WJM, van der Meer JWM, Riksen NP, et al. Trained immunity: adaptation within innate immune mechanisms. PhysiolRev [Internet]. 2023, 103(1):313–46. Available from: http://dx.doi.org/10.1152/physrev.00031.2021

[34] Ravesloot-Chávez MM, Van Dis E, Stanley SA. The innate immune response toMycobacterium tuberculosisinfection. Annu Rev Immunol [Internet]. 2021, 39(1):611–37. Available from: http://dx.doi.org/10.1146/annurev-immunol-093019-010426

[35] Laskowski TJ, Biederstädt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer [Internet]. 2022, 22(10):557–75. Available from: http://dx.doi.org/10.1038/s41568-022-00491-0

[36] Ji T, Li H. T-helper cells and their cytokines in pathogenesis and treatment of asthma. Front Immunol [Internet]. 2023, 14. Available from: http://dx.doi.org/10.3389/fimmu.2023.1149203

[37] Kato H, Nemoto K, Shimizu M, Abe A, Asai S, Ishihama N, et al. Recognition of pathogen-derived sphingolipids in Arabidopsis. Science [Internet]. 2022, 376(6595):857–60. Available from: http://dx.doi.org/10.1126/science.abn0650

[38] Filik K, Szermer-Olearnik B, Oleksy S, Brykała J, Brzozowska E. Bacteriophage tail proteins as a tool for bacterial pathogen recognition—A literature review. Antibiotics (Basel) [Internet]. 2022, 11(5):555. Available from: http://dx.doi.org/10.3390/antibiotics11050555

[39] Kwee BJ, Li X, Nguyen XX, Campagna C, Lam J, Sung KE. Modeling immunity in microphysiological systems. PubMed. 2024, 15353702231215897–15353702231215897.

[40] Ostrowska K, Niewinski P, Piotrowski I, Ostapowicz J, Koczot S, Suchorska WM. Senescence in head and neck squamous cell carcinoma: relationship between senescence-associated secretory phenotype (SASP) mRNA expression level and clinicopathological features. Clinical & Translational Oncology. 2024,

[41] Richardson M. Understanding the structure and function of the skin. Nurs Times. 2003, 99(31):46–8.

[42] Lee H-J, Kim M. Skin barrier function and the microbiome. Int J Mol Sci [Internet]. 2022, 23(21):13071. Available from: http://dx.doi.org/10.3390/ijms232113071

[43] Nguyen AV, Soulika AM. The dynamics of the skin's immune system. Int J Mol Sci [Internet]. 2019, 20(8):1811. Available from: http://dx.doi.org/10.3390/ijms20081811

[44] Swaney MH, Kalan LR. Living in your skin: Microbes, molecules, and mechanisms. Infect Immun [Internet]. 2021, 89(4). Available from: http://dx.doi.org/10.1128/iai.00695-20

[45] Chambers ES, Vukmanovic-Stejic M. Skin barrier immunity and ageing. Immunology [Internet]. 2020, 160(2):116–25. Available from: http://dx.doi.org/10.1111/imm.13152

[46] Natsuga K. Epidermal barriers. Cold Spring Harb Perspect Med [Internet]. 2014, 4(4):a018218–a018218. Available from: http://dx.doi.org/10.1101/cshperspect.a018218

[47] Feng F, Wen Z, Chen J, Yuan Y, Wang C, Sun C. Strategies to develop a mucosa-targeting vaccine against emerging infectious diseases. Viruses [Internet]. 2022, 14(3):520. Available from: http://dx.doi.org/10.3390/v14030520

[48] Hansson GC. Mucins and the microbiome. Annu Rev Biochem [Internet]. 2020, 89(1):769–93. Available from: http://dx.doi.org/10.1146/annurev-biochem-011520-105053

[49] Kalló G, Kumar A, Tőzsér J, Csősz É. Chemical barrier proteins in human body fluids. Biomedicines [Internet]. 2022, 10(7):1472. Available from: http://dx.doi.org/10.3390/biomedicines10071472

[50] Li X, Zuo S, Wang B, Zhang K, Wang Y. Antimicrobial mechanisms and clinical application prospects of antimicrobial peptides. Molecules [Internet]. 2022, 27(9):2675. Available from: http://dx.doi.org/10.3390/molecules27092675

[51] Luo Y, Song Y. Mechanism of antimicrobial peptides: Antimicrobial, anti-inflammatory and antibiofilm activities. Int J Mol Sci [Internet]. 2021, 22(21):11401. Available from: http://dx.doi.org/10.3390/ijms222111401

[52] Vila T, Rizk AM, Sultan AS, Jabra-Rizk MA. The power of saliva: Antimicrobial and beyond. PLoS Pathog [Internet]. 2019, 15(11):e1008058. Available from: http://dx.doi.org/10.1371/journal.ppat.1008058

[53] Ferraboschi P, Ciceri S, Grisenti P. Applications of lysozyme, an innate immune defense factor, as an alternative antibiotic. Antibiotics (Basel) [Internet]. 2021, 10(12):1534. Available from: http://dx.doi.org/10.3390/antibiotics10121534

[54] Frey A, Lunding LP, Ehlers JC, Weckmann M, Zissler UM, Wegmann M. More than just a barrier: The immune functions of the airway epithelium in asthma pathogenesis. Front Immunol [Internet]. 2020, 11. Available from: http://dx.doi.org/10.3389/fimmu.2020.00761

[55] Wertz PW, de Szalay S. Innate antimicrobial defense of skin and oral mucosa. Antibiotics (Basel) [Internet]. 2020, 9(4):159. Available from: http://dx.doi.org/10.3390/antibiotics9040159

[56] Contini C, Olianas A, Serrao S, Deriu C, Iavarone F, Boroumand M, et al. Top-down proteomics of human saliva highlights anti-inflammatory, antioxidant, and antimicrobial defense responses in Alzheimer disease. Front Neurosci [Internet]. 2021, 15. Available from: http://dx.doi.org/10.3389/fnins.2021.668852

[57] Lynge Pedersen AM, Belstrøm D. The role of natural salivary defences in maintaining a healthy oral microbiota. J Dent [Internet]. 2019, 80:S3–12. Available from: http://dx.doi.org/10.1016/j.jdent.2018.08.010

[58] Zhang R, Xu L, Dong C. Antimicrobial peptides: An overview of their structure, functionand mechanism of action. Protein Pept Lett [Internet]. 2022, 29(8):641–50. Available from: http://dx.doi.org/10.2174/0929866529666220613102145

[59] Requena T, Velasco M. The human microbiome in sickness and in health. Rev Clin Esp (Barc) [Internet]. 2021, 221(4):233–40. Available from: http://dx.doi.org/10.1016/j.rceng.2019.07.018

[60] Alemao CA, Budden KF, Gomez HM, Rehman SF, Marshall JE, Shukla SD, et al. Impact of diet and the bacterial microbiome on the mucous barrier and immune disorders. Allergy [Internet]. 2021, 76(3):714–34. Available from: http://dx.doi.org/10.1111/all.14548

[61] Zheng Y, Hunt RL, Villaruz AE, Fisher EL, Liu R, Liu Q, et al. Commensal Staphylococcus epidermidis contributes to skin barrier homeostasis by generating protective ceramides. Cell Host Microbe [Internet]. 2022, 30(3):301-313.e9. Available from: http://dx.doi.org/10.1016/j.chom.2022.01.004

[62] Uberoi A, Bartow-McKenney C, Zheng Q, Flowers L, Campbell A, Knight SAB, et al. Commensal microbiota regulates skin barrier function and repair via signaling through the aryl hydrocarbon receptor. Cell Host Microbe [Internet]. 2021, 29(8):1235-1248.e8. Available from: http://dx.doi.org/10.1016/j.chom.2021.05.011

[63] Şenel S. An overview of physical, microbiological and immune barriers of oral mucosa. Int J Mol Sci [Internet]. 2021, 22(15):7821. Available from: http://dx.doi.org/10.3390/ijms22157821

[64] Grant M, Kilsgård O, Åkerman S, Klinge B, Demmer RT, Malmström J, et al. The human salivary antimicrobial peptide profile according to the oral Microbiota in health, periodontitis and smoking. J Innate Immun [Internet]. 2019, 11(5):432–44. Available from: http://dx.doi.org/10.1159/000494146

[65] Frizinsky S, Haj-Yahia S, Machnes Maayan D, Lifshitz Y, Maoz-Segal R, Offengenden I, et al. The innate immune perspective of autoimmune and autoinflammatory conditions. Rheumatology (Oxford) [Internet]. 2019, 58(Suppl 6):vi1–8. Available from: http://dx.doi.org/10.1093/rheumatology/kez387

[66] Lifshitz Y, Maoz-Segal R, Offengenden I, Kidon M, Agmon-Levin N. Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. Rheumatology [Internet]. 2019, 58(Supplement_6):1–8. Available from: http://dx.doi.org/10.1093/rheumatology/kez387

[67] Haj-Yahia S, Maayan M, Lifshitz D, Maoz-Segal Y, Offengenden R, Kidon I. Insights into Innate Immune Response Against SARS-CoV-2 Infection. Rheumatology [Internet]. 2019, 58(Supplement_6):1–8. Available from: http://dx.doi.org/10.1093/rheumatology/kez387

[68] Muñoz-Wolf N, Lavelle EC. Innate Immune Receptors. In: Methods in Molecular Biology. New York, NY: Springer New York, 2016. p. 1–43.

[69] Mytilineos D, Ezić J, von Witzleben A, Mytilineos J, Lotfi R, Fürst D, et al. Peripheral cytokine levels differ by HPV status and change treatment-dependently in patients with head and neck squamous cell carcinoma. Int J Mol Sci [Internet]. 2020, 21(17):5990. Available from: http://dx.doi.org/10.3390/ijms21175990

[70] Ezić J, Von Witzleben A, Mytilineos J, Lotfi R, Fürst D, Tsamadou C. The role of pro-inflammatory cytokines in the pathogenesis and progression of neoplasms. International Journal of Molecular Sciences [Internet]. 2020, 21(17). Available from: http://dx.doi.org/10.3390/ijms21175990

[71] Von Witzleben A, Mytilineos J, Lotfi R, Fürst D, Tsamadou C, Theodoraki M-N. Effect of the Premalignant and Tumor Microenvironment on Immune Cell Cytokine Production in Head and Neck Cancer. International Journal of Molecular Sciences [Internet]. 2020, 21(17). Available from: http://dx.doi.org/10.3390/ijms21175990

[72] Lee SC, Ferris RL. Immunology of head and neck cancer. In: Head and Neck Cancer. New York, NY: Springer New York, 2011. p. 107–19.

[73] Pries R, Nitsch S, Wollenberg B. Role of cytokines in head and neck squamous cell carcinoma. Expert Review of Anticancer Therapy [Internet]. 2006, 6(9):1195–203. Available from: http://dx.doi.org/10.1586/14737140.6.9.119

[74] Sinha A, Singh V, Tandon R, Mohan Srivastava L. Dichotomy of complement system: Tumorigenesis or destruction. Immunol Lett [Internet]. 2020, 223:89–96. Available from: http://dx.doi.org/10.1016/j.imlet.2020.04.013

[75] Oikonomopoulou K, Reis ES, Lambris JD. Complement system and its role in immune responses. Encyclopedia of Life Sciences [Internet]. 2012, Available from: http://dx.doi.org/10.1002/9780470015902.a0000508.pub3

[76] Orsini F, De Blasio D, Zangari R, Zanier ER, De Simoni M-G. Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front Cell Neurosci [Internet]. 2014, 8:380. Available from: http://dx.doi.org/10.3389/fncel.2014.00380

[77] Althwaiqeb SA, Bordoni B. Histology, B Cell Lymphocyte. StatPearls Publishing, 2023.

[78] B-cells [Internet]. Cleveland Clinic. [cited 2024 Jan 24]. Available from: https://my.clevelandclinic.org/health/body/24669-b-cells

[79] Pierce SK. Understanding B cell activation: from single molecule tracking, through Tolls, to stalking memory in malaria. Immunol Res [Internet]. 2009, 43(1–3):85–97. Available from: http://dx.doi.org/10.1007/s12026-008-8052-y

[80] Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. B-cell activation by armed helper T cells. London, England: Garland Science, 2001.

[81] Tsai D-Y, Hung K-H, Chang C-W, Lin K-I. Regulatory mechanisms of B cell responses and the implication in B cell-related diseases. J Biomed Sci [Internet]. 2019, 26(1):64. Available from: http://dx.doi.org/10.1186/s12929-019-0558-1

[82] Luz Elena Cano R, Lopera HDE. Introduction to T and B lymphocytes. El Rosario University Press, 2013.

[83] Eberle C. Antibody production simply explained - evitria [Internet]. evitria -. evitria AG, 2023 [cited 2024 Jan 24]. Available from: https://www.evitria.com/journal/antibodies/antibody-production/

[84] Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. B Cells and Antibodies. London, England: Garland Science, 2002.

[85] Sauls RS, McCausland C, Taylor BN. Histology, T-Cell Lymphocyte. StatPearlsPublishing, 2023.

[86] Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. T cell-mediated immunity. London, England: Garland Science, 2001.

[87] Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. T cell-mediated cytotoxicity. London, England: Garland Science, 2001.

[88] Jbc.org. [cited 2024 Jan 24]. Available from: https://www.jbc.org/content/early/2019/12/17/jbc.REV119.009411.full.pdf

[89] Understanding immunological memory [Internet]. Asm.org. 2023 [cited 2024 Jan 24]. Available from: https://asm.org/Articles/2023/May/Understanding-Immunological-Memory

[90] Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunological memory. London, England: Garland Science, 2001.

[91] Alm A, Henry C. Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination. Frontiers in Immunology. 2019, 10.

[92] Lin K, Chen S, Chen G. Role of memory T cells and perspectives for intervention in organ transplantation. Front Immunol [Internet]. 2015 [cited 2024 Jan 24], 6. Available from: http://dx.doi.org/10.3389/fimmu.2015.00473

[93] Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. Nat Rev Immunol [Internet]. 2020 [cited 2024 Jan 24], 20(4):229–38. Available from: https://www.nature.com/articles/s41577-019-0244-2

[94] Iborra S, Hidalgo A. General and emerging concepts of immunity. In: Encyclopedia of Cell Biology. Elsevier, 2023. p. 510–25.

[95] Ito T, Connett JM, Kunkel SL, Matsukawa A. The linkage of innate and adaptive immune response during granulomatous development. Front Immunol [Internet]. 2013, 4:10. Available from: http://dx.doi.org/10.3389/fimmu.2013.00010

[96] Gasteiger G, Rudensky AY. Interactions between innate and adaptive lymphocytes. Nat Rev Immunol [Internet]. 2014, 14(9):631–9. Available from: http://dx.doi.org/10.1038/nri3726

[97] Bousser D, Callewaert E, Festjens N. T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy. Cancers. 2021, 13.

[98] Greenspan NS. A disquisition on MHC restriction and T cell recognition in five acts. Viral Immunol [Internet]. 2020, 33(3):153–9. Available from: http://dx.doi.org/10.1089/vim.2019.0182

[99] Clark R, Kupper T. Old meets new: the interaction between innate and adaptive immunity. J Invest Dermatol [Internet]. 2005, 125(4):629–37. Available from: http://dx.doi.org/10.1111/j.0022-202X.2005.23856.x

[100] Rosales C. Neutrophils at the crossroads of innate and adaptive immunity. J Leukoc Biol [Internet]. 2020, 108(1):377–96. Available from: http://dx.doi.org/10.1002/JLB.4MIR0220-574RR

[101] Li Y, Wang W, Yang F, Xu Y, Feng C, Zhao Y. The regulatory roles of neutrophils in adaptive immunity. Cell Commun Signal [Internet]. 2019, 17(1):147. Available from: http://dx.doi.org/10.1186/s12964-019-0471-y

[102] McDaniel MM, Meibers HE, Pasare C. Innate control of adaptive immunity and adaptive instruction of innate immunity: bi-directional flow of information. Curr Opin Immunol [Internet]. 2021, 73:25–33. Available from: http://dx.doi.org/10.1016/j.coi.2021.07.013

[103] Duque A, Descoteaux G. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014, 5.

[104] Rastogi I, Jeon D, Moseman JE, Muralidhar A, Potluri HK, McNeel DG. Role of B cells as antigen presenting cells. Front Immunol [Internet]. 2022, 13:954936. Available from: http://dx.doi.org/10.3389/fimmu.2022.954936

[105] Muntjewerff EM, Meesters LD, van den Bogaart G. Antigen cross-presentation by macrophages. Front Immunol [Internet]. 2020, 11:1276. Available from: http://dx.doi.org/10.3389/fimmu.2020.01276

[106] Rahman A, Tiwari A, Narula J, Hickling T. Importance of feedback and feedforward loops to adaptive immune response modeling. CPT Pharmacometrics Syst Pharmacol [Internet]. 2018, 7(10):621–8. Available from: http://dx.doi.org/10.1002/psp4.12352

[107] Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+T cells: differentiation and functions. Clin Dev Immunol [Internet]. 2012, 2012:925135. Available from: http://dx.doi.org/10.1155/2012/925135

[108] Meegalla N, Downs BW. Anatomy, head and neck, palatine tonsil (faucial tonsils). StatPearls Publishing, 2023.

[109] Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol [Internet]. 2003, 62(6):593–604. Available from: http://dx.doi.org/10.1093/jnen/62.6.593

[110] Proulx ST, Engelhardt B. Central nervous system zoning: How brain barriers establish subdivisions for CNS immune privilege and immune surveillance. J Intern Med [Internet]. 2022, 292(1):47–67. Available from: http://dx.doi.org/10.1111/joim.13469

[111] Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, del Zoppo GJ, Doolittle ND, et al. Immunologic privilege in the central nervous system and the blood–brain barrier. J CerebBlood Flow Metab [Internet]. 2013, 33(1):13–21. Available from: http://dx.doi.org/10.1038/jcbfm.2012.153

[112] Sethi D, Gofur EM, Munakomi S. Anatomy, head and neck: Carotid arteries. StatPearlsPublishing, 2023.

[113] Hordijk PL. Endothelial signalling events during leukocyte transmigration. FEBS J [Internet]. 2006, 273(19):4408–15. Available from: http://dx.doi.org/10.1111/j.1742-4658.2006.05440.x

[114] Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation [Internet]. 1990, 50(4):537–44. Available from: http://dx.doi.org/10.1097/00007890-199010000-00001

[115] Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers [Internet]. 2020, 6(1). Available from: http://dx.doi.org/10.1038/s41572-020-00224-3

[116] Roesch ZK, Tadi P. Anatomy, Head and Neck, Neck. StatPearls Publishing, 2023.

[117] Shah A, Cunha B. Anatomy, head and neck: Anterior cervical region. StatPearlsPublishing, 2023.

[118] Perri F, Ionna F, Longo F, Della Vittoria Scarpati G, De Angelis C, Ottaiano A, et al. Immune response against head and neck cancer: Biological mechanisms and implication on therapy. Transl Oncol [Internet]. 2020, 13(2):262–74. Available from: http://dx.doi.org/10.1016/j.tranon.2019.11.008

[119] Stradsson T, Sellberg F, Berglund D, Ehrsson YT, Laurell G. Systemic Inflammatory Reaction in Patients With Head and Neck Cancer-An Explorative Study. Front Oncol. 2019, 9.

[120] Chaplin DD. Overview of the immune response. J Allergy Clin Immunol [Internet]. 2010, 125(2 Suppl 2):S3-23. Available from: http://dx.doi.org/10.1016/j.jaci.2009.12.980

[121] Drexler M, Institute of Medicine (US). How infection works. Washington, D.C., DC: National Academies Press, 2010.

[122] Cesta MF. Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol [Internet]. 2006, 34(5):599–608. Available from: http://dx.doi.org/10.1080/01926230600865531

[123] Mullangi S, Lekkala MR. Mucosa-Associated Lymphoma Tissue. StatPearls Publishing, 2023.

[124] Breslin JW, Yang Y, Scallan JP, Sweat RS, Adderley SP, Murfee WL. Lymphatic vessel network structure and physiology. Compr Physiol [Internet]. 2018, 9(1):207–99. Available from: http://dx.doi.org/10.1002/cphy.c180015

[125] Liao S, Padera TP. Lymphatic function and immune regulation in health and disease. Lymphat Res Biol [Internet]. 2013, 11(3):136–43. Available from: http://dx.doi.org/10.1089/lrb.2013.0012

[126] Jensen PE. Mechanisms of antigen presentation. Clin Chem Lab Med [Internet]. 1999, 37(3):179–86. Available from: http://dx.doi.org/10.1515/CCLM.1999.034

[127] Bujoreanu I, Gupta V. Anatomy, lymph nodes. StatPearls Publishing, 2023.

[128] McNeill E, Houston R. Diseases of the adenoids and tonsils in children. Surgery [Internet]. 2021, 39(9):617–24. Available from: http://dx.doi.org/10.1016/j.mpsur.2021.08.003

[129] Zachary JF. Mechanisms of microbial infections. In: Pathologic Basis of Veterinary Disease. Elsevier, 2017. p. 132-241.e1.

[130] Walker DH. Interactions of pathogens with the host. In: Pathobiology of Human Disease. Elsevier, 2014. p. 214–6.

[131] Fossum CC, Chintakuntlawar AV, Price DL, Garcia JJ. Characterization of the oropharynx: anatomy, histology, immunology, squamous cell carcinoma and surgical resection. Histopathology [Internet]. 2017, 70(7):1021–9. Available from: http://dx.doi.org/10.1111/his.13140

[132] Nave H, Gebert A, Pabst R. Morphology and immunology of the human palatine tonsil. Anat Embryol (Berl) [Internet]. 2001, 204(5):367–73. Available from: http://dx.doi.org/10.1007/s004290100210

[133] Grebennikov D, Savinkov R, Zelenova E, Lobov G, Bocharov G. Network Modeling of Murine Lymphatic System. Algorithms. 2023, 16(3).

[134] Arambula A, Brown JR, Neff L. Anatomy and physiology of the palatine tonsils, adenoids, and lingual tonsils. World J Otorhinolaryngol Head Neck Surg [Internet]. 2021, 7(3):155–60. Available from: http://dx.doi.org/10.1016/j.wjorl.2021.04.003

[135] Hett GS, Butterfield HG. The anatomy of the palatine tonsils. J Anat Physiol. 1909, 44(Pt 1):35–55.

[136] Perry ME. The specialised structure of crypt epithelium in the human palatine tonsil and its functional significance. J Anat. 1994, 185 (Pt 1):111–27.

[137] Grebennikov D, Savinkov R, Zelenova E, Lobov G, Bocharov G. Network Modeling of Murine Lymphatic System. Algorithms. 2023, 16(3).

[138] Stanisce L, Sims E, Hou C, Koshkareva Y, Gaughan JP, Kuzin I, et al. Differential cellular composition of human palatine and pharyngeal tonsils. Arch Oral Biol [Internet]. 2018, 96:80–6. Available from: http://dx.doi.org/10.1016/j.archoralbio.2018.08.020

[139] Jovi M, Avramovi V, Vlahovi P, Savi V, Veli A, Petrovi V. Ultrastructure of the human palatine tonsil and its functional significance.

[140] De Martin A, Stanossek Y, Pikor NB, Ludewig B. Protective fibroblastic niches in secondary lymphoid organs. J Exp Med [Internet]. 2024, 221(1). Available from: http://dx.doi.org/10.1084/jem.20221220

[141] den Haan JMM, Arens R, van Zelm MC. The activation of the adaptive immune system: cross-talk between antigen-presenting cells, T cells and B cells. Immunol Lett [Internet]. 2014, 162(2 Pt B):103–12. Available from: http://dx.doi.org/10.1016/j.imlet.2014.10.011

[142] Buettner M, Bode U. Lymph node dissection - understanding the immunological function of lymph nodes. Clin Exp Immunol. 2012, 169(3):205–12.

[143] Koroulakis A, Jamal Z, Agarwal M. Anatomy, head and neck, lymph nodes. StatPearlsPublishing, 2022.

[144] Hoffman W, Lakkis FG, Chalasani G. B cells, antibodies, and more. Clin J Am Soc Nephrol [Internet]. 2016, 11(1):137–54. Available from: http://dx.doi.org/10.2215/CJN.09430915

[145] Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Helper T Cells and Lymphocyte Activation. London, England: Garland Science, 2002.

[146] Gaffen SL, Moutsopoulos NM. Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity. Sci Immunol [Internet]. 2020, 5(43):eaau4594. Available from: http://dx.doi.org/10.1126/sciimmunol.aau4594

[147] Hamel KM, Liarski VM, Clark MR. Germinal center B-cells. Autoimmunity [Internet]. 2012, 45(5):333–47. Available from: http://dx.doi.org/10.3109/08916934.2012.665524

[148] Carr I. Lymphatic metastasis. Cancer Metastasis Rev [Internet]. 1983, 2(3):307–17. Available from: http://dx.doi.org/10.1007/bf00048483

[149] Zhou H, Lei P-J, Padera TP. Progression of metastasis through lymphatic system. Cells [Internet]. 2021, 10(3):627. Available from: http://dx.doi.org/10.3390/cells10030627

[150] Ptasiewicz M, Grywalska E, Mertowska P, Korona-Głowniak I, Poniewierska-Baran A, Niedźwiedzka-Rystwej P, et al. Armed to the teeth-the oral mucosa immunity system and Microbiota. Int J Mol Sci [Internet]. 2022, 23(2):882. Available from: http://dx.doi.org/10.3390/ijms23020882

[151] Wu R-Q, Zhang D-F, Tu E, Chen Q-M, Chen W. The mucosal immune system in the oral cavity-an orchestra of T cell diversity. Int J Oral Sci [Internet]. 2014, 6(3):125–32. Available from: http://dx.doi.org/10.1038/ijos.2014.48

[152] Parker D, Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol [Internet]. 2011, 45(2):189–201. Available from: http://dx.doi.org/10.1165/rcmb.2011-0011RT

[153] Gopallawa I, Dehinwal R, Bhatia V, Gujar V, Chirmule N. A four-part guide to lung immunology: Invasion, inflammation, immunity, and intervention. Front Immunol [Internet]. 2023, 14:1119564. Available from: http://dx.doi.org/10.3389/fimmu.2023.1119564

[154] Hartl D, Tirouvanziam R, Laval J, Greene CM, Habiel D, Sharma L, et al. Innate immunity of the lung: From basic mechanisms to translational medicine. J Innate Immun [Internet]. 2018, 10(5–6):487–501. Available from: http://dx.doi.org/10.1159/000487057

[155] Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res [Internet]. 2020, 30(6):492–506. Available from: http://dx.doi.org/10.1038/s41422-020-0332-7

[156] Willis JR, Gabaldón T. The human oral microbiome in health and disease: From sequences to ecosystems. Microorganisms [Internet]. 2020, 8(2):308. Available from: http://dx.doi.org/10.3390/microorganisms8020308

[157] Ahmad HI, Jabbar A, Mushtaq N, Javed Z, Hayyat MU, Bashir J, et al. Immune tolerance vs. Immune resistance: The interaction between host and pathogens in infectious diseases. Front Vet Sci [Internet]. 2022, 9:827407. Available from: http://dx.doi.org/10.3389/fvets.2022.827407

[158] Mavragani CP, Moutsopoulos HM. Sjögren syndrome. CMAJ [Internet]. 2014, 186(15):E579–86. Available from: http://dx.doi.org/10.1503/cmaj.122037

[159] Justiz Vaillant AA, Vashisht R, Zito PM. Immediate hypersensitivity reactions. StatPearlsPublishing, 2023.

[160] Abbas M, Moussa M, Akel H. Type I Hypersensitivity Reaction. StatPearls Publishing, 2023.

[161] Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol [Internet]. 2015, 33(29):3293–304. Available from: http://dx.doi.org/10.1200/JCO.2015.61.1509

[162] Cleary JO, Sivarasan N, Burd C, Connor SEJ. Head and neck manifestations of granulomatosis with polyangiitis. Br J Radiol [Internet]. 2021, 94(1119):20200914. Available from: http://dx.doi.org/10.1259/bjr.20200914

[163] Ikeda R, Kurakami K, Ohta N, Suzuki T, Saito Y, Kusano Y, et al. Malignancies in patients with IgG4-related diseases in head and neck regions. Tohoku J Exp Med [Internet]. 2019, 249(4):285–90. Available from: http://dx.doi.org/10.1620/tjem.249.285

[164] Chakraborty R, Darido C, Liu F, Maselko M, Ranganathan S. Head and neck cancer immunotherapy: Molecular biological aspects of preclinical and clinical research. Cancers (Basel) [Internet]. 2023, 15(3). Available from: http://dx.doi.org/10.3390/cancers15030852

[165] Jiang Z, Li Y, Wu C, Zhao Y, Zhan Q, Wang K. Global research trends in immunotherapy for head and neck neoplasms: A scientometric study. 2023.

[166] Pereira D, Martins D, Mendes F. Immunotherapy in head and neck cancer when, how, and why? Biomedicines [Internet]. 2022, 10(9):2151. Available from: http://dx.doi.org/10.3390/biomedicines10092151

[167] Chen S, Yang Y, Wang R, Fang J. Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis. 2023.

[168] Li J, Xiao Y, Yu H, Jin X, Fan S, Liu W. Mutual connected IL-6, EGFR and LIN28/Let7-related mechanisms modulate PD-L1 and IGF upregulation in HNSCC using immunotherapy. Front Oncol [Internet]. 2023, 13:1140133. Available from: http://dx.doi.org/10.3389/fonc.2023.1140133

[169] Nindra U, Hurwitz J, Forstner D, Chin V, Gallagher R, Liu J. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma. Cancer Med [Internet]. 2023, 12(10):11234–47. Available from: http://dx.doi.org/10.1002/cam4.5815

[170] Kim SY, Song YS, Wee JH, Min C, Yoo DM, Choi HG. Association between Ménière's disease and thyroid diseases: a nested case–control study. Sci Rep [Internet]. 2020, 10(1):18224. Available from: http://dx.doi.org/10.1038/s41598-020-75404-y

[171] Chen S, Tan L, Qin D, Lv H, Liu K, Xu Y, et al. The causal relationship between multiple autoimmune diseases and nasal polyps. Front Immunol [Internet]. 2023, 14:1228226. Available from: http://dx.doi.org/10.3389/fimmu.2023.1228226

[172] Álvarez-Sierra D, Rodríguez-Grande J, Gómez-Brey A, Bello I, Caubet E, González Ó, et al. Single cell transcriptomic analysis of Graves' disease thyroid glands reveals the broad immunoregulatory potential of thyroid follicular and stromal cells and implies a major re-interpretation of the role of aberrant HLA class II expression in

autoimmunity. J Autoimmun [Internet]. 2023, 139(103072):103072. Available from: http://dx.doi.org/10.1016/j.jaut.2023.103072

[173] Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I. Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Practice & Research Clinical Endocrinology &amp. Metabolism [Internet]. 2020, 34(1). Available from: http://dx.doi.org/10.1016/j.beem.2020.101388

[174] Chu H, Kim SM, Zhang K, Wu Z, Lee H, Kim JH, et al. Head and neck dermatitis is exacerbated by Malassezia furfur colonization, skin barrier disruption, and immune dysregulation. Front Immunol [Internet]. 2023, 14:1114321. Available from: http://dx.doi.org/10.3389/fimmu.2023.1114321

[175] Xavier FCA, Silva JC, Rodini CO, Rodrigues MFSD. Mechanisms of immune evasion by head and neck cancer stem cells. Front Oral Health [Internet]. 2022, 3:957310. Available from: http://dx.doi.org/10.3389/froh.2022.957310

[176] Perri F, Ionna F, Longo F, Scarpati DV, Angelis D, Ottaiano C. Immune response against head and neck cancer: Biological Mechanisms and implication on therapy. Translational Oncology [Internet]. 2020, 13(2):262–74. Available from: http://dx.doi.org/10.1016/j.tranon.2019.11.00

[177] Celik IH, Hanna M, Canpolat FE, Pammi M. Diagnosis of neonatal sepsis: the past, present and future. Pediatr Res [Internet]. 2022, 91(2):337–50. Available from: http://dx.doi.org/10.1038/s41390-021-01696-z

[178] Joshi K, Milighetti M, Chain BM. Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy. Curr Opin Immunol [Internet]. 2022, 74:1–8. Available from: http://dx.doi.org/10.1016/j.coi.2021.07.006

[179] Pauken KE, Lagattuta KA, Lu BY, Lucca LE, Daud AI, Hafler DA, et al. TCR-sequencing in cancer and autoimmunity: barcodes and beyond. Trends Immunol [Internet]. 2022, 43(3):180–94. Available from: http://dx.doi.org/10.1016/j.it.2022.01.002

[180] Wang S, Sun S-T, Zhang X-Y, Ding H-R, Yuan Y, He J-J, et al. The evolution of single-cell RNA sequencing technology and application: Progress and perspectives. Int J Mol Sci [Internet]. 2023, 24(3):2943. Available from: http://dx.doi.org/10.3390/ijms24032943

[181] Bukhari S, Henick BS, Winchester RJ, Lerrer S, Adam K, Gartshteyn Y, et al. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep Med [Internet]. 2023, 4(1):100868. Available from: http://dx.doi.org/10.1016/j.xcrm.2022.100868

[182] Pizzolato G, Kaminski H, Tosolini M, Franchini D-M, Pont F, Martins F, et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes. Proc Natl Acad Sci U S A [Internet]. 2019, 116(24):11906–15. Available from: http://dx.doi.org/10.1073/pnas.1818488116

[183] Green JJ. Immunoengineering has arrived. J Biomed Mater Res A [Internet]. 2021, 109(4):397–403. Available from: http://dx.doi.org/10.1002/jbm.a.37041

[184] Gammon JM, Jewell CM. Engineering immune tolerance with biomaterials. Adv HealthcMater [Internet]. 2019, 8(4). Available from: http://dx.doi.org/10.1002/adhm.201801419

[185] Zanganeh S, Georgala P, Corbo C, Arabi L, Ho JQ, Javdani N, et al. Immunoengineering in glioblastoma imaging and therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol[Internet]. 2019, 11(6). Available from: http://dx.doi.org/10.1002/wnan.1575

[186] Kandari D, Bhatnagar R. Antibody engineering and its therapeutic applications. Int Rev Immunol [Internet]. 2023, 42(2):156–83. Available from: http://dx.doi.org/10.1080/08830185.2021.1960986

[187] Liu Y, Hardie J, Zhang X, Rotello VM. Effects of engineered nanoparticles on the innate immune system. Semin Immunol [Internet]. 2017, 34:25–32. Available from: http://dx.doi.org/10.1016/j.smim.2017.09.011

[188] Algar WR, Massey M, Rees K, Higgins R, Krause KD, Darwish GH, et al. Photoluminescent nanoparticles for chemical and biological analysis and imaging. Chem Rev [Internet]. 2021, 121(15):9243–358. Available from: http://dx.doi.org/10.1021/acs.chemrev.0c01176

[189] Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol [Internet]. 2020, 20(6):375–88. Available from: http://dx.doi.org/10.1038/s41577-020-0285-6

[190] Mulder WJM, Ochando J, Joosten LAB, Fayad ZA, Netea MG. Therapeutic targeting of trained immunity. Nat Rev Drug Discov [Internet]. 2019, 18(7):553–66. Available from: http://dx.doi.org/10.1038/s41573-019-0025-4

[191] Riksen NP. Trained immunity and atherosclerotic cardiovascular disease. Curr Opin Lipidol[Internet]. 2019, 30(5):395–400. Available from: http://dx.doi.org/10.1097/mol.0000000000000628

[192] Bindu S, Dandapat S, Manikandan R, Dinesh M, Subbaiyan A, Mani P, et al. Prophylactic and therapeutic insights into trained immunity: A renewed concept of innate immune memory. Hum Vaccin Immunother [Internet]. 2022, 18(1). Available from: http://dx.doi.org/10.1080/21645515.2022.2040238

[193] Penkov S, Mitroulis I, Hajishengallis G, Chavakis T. Immunometabolic crosstalk: An ancestral principle of trained immunity? Trends Immunol [Internet]. 2019, 40(1):1–11. Available from: http://dx.doi.org/10.1016/j.it.2018.11.002

[194] Irvine DJ, Maus MV, Mooney DJ, Wong WW. The future of engineered immune cell therapies. Science [Internet]. 2022, 378(6622):853–8. Available from: http://dx.doi.org/10.1126/science.abq6990

[195] Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in universal CAR-T cell therapy. Front Immunol [Internet]. 2021, 12. Available from: http://dx.doi.org/10.3389/fimmu.2021.744823

[196] Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov [Internet]. 2020, 19(3):185–99. Available from: http://dx.doi.org/10.1038/s41573-019-0051-2

[197] Morgan MA, Büning H, Sauer M, Schambach A. Use of cell and genome modification technologies to generate improved "off-the-shelf" CAR T and CAR NK cells. Front Immunol [Internet]. 2020, 11. Available from: http://dx.doi.org/10.3389/fimmu.2020.01965

[198] Zhang Y, Li P, Fang H, Wang G, Zeng X. Paving the way towards universal chimeric antigen receptor therapy in cancer treatment: Current landscape and progress. Front Immunol [Internet]. 2020, 11. Available from: http://dx.doi.org/10.3389/fimmu.2020.604915

[199] Subramanian M, Wojtusciszyn A, Favre L, Boughorbel S, Shan J, Letaief KB, et al. Precision medicine in the era of artificial intelligence: implications in chronic disease management. J Transl Med [Internet]. 2020, 18(1). Available from: http://dx.doi.org/10.1186/s12967-020-02658-5

[200] Pandya S, Thakur A, Saxena S, Jassal N, Patel C, Modi K, et al. A study of the recent trends of immunology: Key challenges, domains, applications, datasets, and future directions. Sensors (Basel) [Internet]. 2021, 21(23):7786. Available from: http://dx.doi.org/10.3390/s21237786

[201] Yu J, Hu Y, Xu Y, Wang J, Kuang J, Zhang W, et al. LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features. BMC Cancer [Internet]. 2019, 19(1). Available from: http://dx.doi.org/10.1186/s12885-019-5433-7

[202] Jabbari P, Rezaei N. Artificial intelligence and immunotherapy. Expert Rev Clin Immunol [Internet]. 2019, 15(7):689–91. Available from: http://dx.doi.org/10.1080/1744666X.2019.1623670

[203] Ogulur I, Pat Y, Ardicli O, Barletta E, Cevhertas L, Fernandez-Santamaria R, et al. Advances and highlights in biomarkers of allergic diseases. Allergy [Internet]. 2021, 76(12):3659–86. Available from: http://dx.doi.org/10.1111/all.15089

[204] Bakker D, de Bruin-Weller M, Drylewicz J, van Wijk F, Thijs J. Biomarkers in atopic dermatitis. J Allergy Clin Immunol [Internet]. 2023, 151(5):1163–8. Available from: http://dx.doi.org/10.1016/j.jaci.2023.01.019

[205] Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril [Internet]. 2018, 109(6):952–63. Available from: http://dx.doi.org/10.1016/j.fertnstert.2018.05.006

[206] Banerjee S, Prabhu Basrur N, Rai PS. Omics technologies in personalized combination therapy for cardiovascular diseases: challenges and opportunities. Per Med [Internet]. 2021, 18(6):595–611. Available from: http://dx.doi.org/10.2217/pme-2021-0087

[207] Breiteneder H, Peng Y-Q, Agache I, Diamant Z, Eiwegger T, Fokkens WJ, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy [Internet]. 2020, 75(12):3039–68. Available from: http://dx.doi.org/10.1111/all.14582

[208] Boutin RCT, Sbihi H, Dsouza M, Malhotra R, Petersen C, Dai D, et al. Mining the infant gut microbiota for therapeutic targets against atopic disease. Allergy [Internet]. 2020, 75(8):2065–8. Available from: http://dx.doi.org/10.1111/all.14244

[209] Kucuksezer UC, Ozdemir C, Yazici D, Pat Y, Mitamura Y, Li M, et al. The epithelial barrier theory: Development and exacerbation of allergic and other chronic inflammatory diseases. Asia Pac Allergy [Internet]. 2023, 13(1):28–39. Available from: http://dx.doi.org/10.5415/apallergy.0000000000000005

[210] Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol [Internet]. 2021, 21(11):739–51. Available from: http://dx.doi.org/10.1038/s41577-021-00538-7

[211] Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, et al. Enabling technologies for personalized and precision medicine. Trends Biotechnol [Internet]. 2020, 38(5):497–518. Available from: http://dx.doi.org/10.1016/j.tibtech.2019.12.021

[212] Cheng X, Fan S, Wen C, Du X. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges. Brief Funct Genomics [Internet]. 2020, 19(3):209–14. Available from: http://dx.doi.org/10.1093/bfgp/elaa001

[213] Sharma G, Sharma AR, Bhattacharya M, Lee S-S, Chakraborty C. CRISPR-Cas9: A preclinical and clinical perspective for the treatment of human diseases. Mol Ther [Internet]. 2021, 29(2):571–86. Available from: http://dx.doi.org/10.1016/j.ymthe.2020.09.028

[214] Lee MH, Shin JI, Yang JW, Lee KH, Cha DH, Hong JB, et al. Genome editing using CRISPR-Cas9 and autoimmune diseases: A comprehensive review. Int J Mol Sci [Internet]. 2022, 23(3):1337. Available from: http://dx.doi.org/10.3390/ijms23031337

[215] Italiani P, Della Camera G, Boraschi D. Induction of innate immune memory by engineered nanoparticles in monocytes/macrophages: From hypothesis to reality. Front Immunol [Internet]. 2020, 11. Available from: http://dx.doi.org/10.3389/fimmu.2020.566309

[216] Mohammadzadeh I, Qujeq D, Yousefi T, Ferns GA, Maniati M, Vaghari-Tabari M. CRISPR/Cas9 gene editing: A new therapeutic approach in the treatment of infection and autoimmunity. IUBMB Life [Internet]. 2020, 72(8):1603–21. Available from: http://dx.doi.org/10.1002/iub.2296